NCT00804154View on ClinicalTrials.gov

Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

August 14, 2009

Primary Completion Date

February 7, 2026

Study Completion Date

February 7, 2026

Conditions
Intractable PainPalliative Care
Interventions
DRUG

Intrathecal Resiniferatoxin

phase I, single-site, non-randomized, open-label, dose-escalation study to determine the safety and efficacy of IT RTX in subjects with severe refractory pain due to advanced malignancy

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

collaborator

Sorrento Therapeutics, Inc.

INDUSTRY

lead

National Institute of Dental and Craniofacial Research (NIDCR)

NIH